Myomo earnings release, May 7, 2026

Myomo, Inc. (MYO) · Form 8-K, Item 2.02 · Filed · SEC filing

Myomo Reports First Quarter 2026 Financial and Operating Results

Revenue of $10.1 million with 49% of first quarter revenue from recurring patient sources

MyoPro® orders received during the quarter were up 12% year-over-year

Expanded gross margin, lower operating expenses and narrowed net loss

Conference call begins at 4:30pm Eastern time today

BURLINGTON, Mass. (May 7, 2026) – Myomo, Inc. (NYSE American: MYO)

(“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2026.

“Earlier this year we established four success pillars for 2026, including growing revenue from recurring patient sources, increasing market access, demonstrating operating leverage and investing in innovation. With strong progress against each, first quarter revenue and operating results were above our targets. We are effectively shifting our business toward recurring patient sources, which represented 49% of revenue in the quarter, up from 25% a year ago. Our MyoConnect program is ramping up nicely and enhancing the clinical quality of prospective patients as well. This resulted in 11% of pipeline adds and 16% of orders generated by direct billing referrals in the quarter, with the added benefit of a sequential decline in cost per pipeline add," said Paul Gudonis, Myomo's Chairman and Chief Executive Officer.

Success Pillar Accomplishments:

• Shift to Recurring Patient Sources:

49% of first quarter revenue was derived from recurring patient sources, up from 42% in the fourth quarter of 2025 and 25% in the first quarter of 2025. Revenue from the U.S. O&P channel increased 79% year-over-year.

• Increase Market Access with Additional Payer Contracts:

The Company continues to expand in-network payer access, including new state contracts with Elevance's Anthem Blue Cross Blue Shield Network as previously announced, with additional contracts pending. Once finalized, Myomo will have in-network access to approximately 158 million covered lives, up from 9 million covered lives two years ago. In-network access increases revenue velocity and is already having a positive effect on authorization rates.

• Demonstrate Operating Leverage:

Revenues increased 3% year-over-year, while operating expenses decreased 1%. In addition, gross margin expanded by 100 basis points year-over year, contributing to a 20% improvement in Adjusted EBITDA.

• Invest in Product Development and Clinical Research:

The Company recently launched the Myomo Mobile App, a new tool designed to support clinicians and patients throughout the MyoPro experience. The Mobile App replaces a laptop computer that was previously provided to every MyoPro patient, thereby improving practitioner and patient access while reducing the Company's material cost by more than 10%. The randomized controlled trial underway at the University of Utah has enrolled 18 of a planned 50 subjects, which, if successful, is expected to lead to higher authorization rates from Medicare Advantage payers.

Results of Key Operating Metrics:

• 723 patients were added to the pipeline in the first quarter of 2026, up 7% sequentially, while cost per pipeline add was $2,550, down 16% sequentially;

• 239 orders were received in the first quarter of 2026, up 12% year-over-year; and

• Backlog as of March 31, 2026 was 226 patients, up 14% compared with December 31, 2025.

Financial Results

Revenue:

Revenue for the first quarter of 2026 was $10.1 million, up 3% compared with the first quarter of 2025, reflecting a higher average selling price ("ASP"), partially offset by a modest decrease in the number of revenue units. ASP was approximately $58,800, up 9% versus the prior year. Myomo recognized revenue on 172 MyoPro units in the quarter, down 5% over the same period a year ago. Medicare Part B patients represented 51% of first quarter 2026 revenue.

Gross Margin:

Gross margin for the first quarter of 2026 was 68.2%, compared with 67.2% for the first quarter of 2025. The increase was driven primarily by the higher ASP, partially offset by higher clinical costs classified to cost of goods sold.

Operating Expenses:

Operating expenses for the first quarter of 2026 were $10.1 million, a decrease of 1% compared with the first quarter of 2025. The decrease was primarily due to lower research and development and general and administrative expenses, partially offset by higher sales, clinical and marketing expenses, including higher advertising expense. Cost per pipeline add was $2,550, down 16% sequentially and up 11% compared with the same period a year ago.

Operating and Net Loss:

Operating loss for the first quarter of 2026 was $3.2 million, compared with an operating loss of $3.5 million for the first quarter of 2025. Net loss for the first quarter of 2026 was $3.0 million, or $0.07 per share, compared with a net loss of $3.5 million, or $0.08 per share, for the first quarter of 2025.

Adjusted EBITDA:

Adjusted EBITDA for the first quarter of 2026 was $(2.3) million, compared with $(2.8) million for the first quarter of 2025. A reconciliation of GAAP net loss to this non-GAAP financial measure appears below.

Cash, Cash Equivalents and Cash Flows:

Cash, cash equivalents and short-term investments as of March 31, 2026, were $15.7 million. Cash used in operating activities was $2.2 million for the first quarter of 2026, compared with $2.7 million used in operating activities in the first quarter of 2025.

Business Outlook... (truncated)illion. We reaffirm our guidance for full year revenue to be in the range of $43 million to $46 million and our prior full-year operating leverage expectation."

Conference Call and Webcast

Myomo will hold a conference call today at 4:30 p.m. Eastern time to discuss these results and answer questions. Participants are encouraged to pre-register for the call at this link. Callers who pre-register will receive a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time up to and after the start of the call. Those unable to pre-register may participate by dialing 844-707-6932 (U.S.) or 412-317-9250 (International). A webcast of the call will also be available at Myomo’s Investor Relations page at http://ir.myomo.com/.

A replay of the webcast will be available beginning approximately one hour after the completion of the live conference call at http://ir.myomo.com/. A dial-in replay of the call will be available until May 21, 2026 at 855-669-9658 (U.S./Canada toll-free) or 412-317-0088 (International), with passcode 8935228.

Non-GAAP Financial Measures

Myomo is providing financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. This information includes Adjusted EBITDA. This non-GAAP financial measure is not in accordance with, or an alternative for, GAAP and may be different from similar non-GAAP financial measures used by other companies. Myomo believes the use of this non-GAAP financial measure provides supplementary information for investors to use in evaluating operating performance and in comparing Myomo’s financial measures with other companies in its industry, many of which present similar non-GAAP financial measures. Adjusted EBITDA is EBITDA adjusted for stock-based compensation expense. This non-GAAP financial measure is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP, and should be viewed in conjunction with GAAP financial measures. Investors are encouraged to review the reconciliation of this non-GAAP measure to its most directly comparable GAAP financial measure. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables included as part of this press release.

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

Financial statements

Income Statement

For the Three Months Ended March 31, — Financial Results

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025Period- to-Period Change – $$Period- to-Period Change – %
Revenue10,113,2889,831,814281,4743.0%
Cost of revenue3,211,6823,222,184-10,502-0.0%
Gross profit6,901,6066,609,630291,9764.0%
Gross margin %68.2%67.21.0%

Income Statement

For the Three Months Ended — CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months Ended – March 31, – 2026For the Three Months Ended – March 31, – 2025
Revenue10,113,2889,831,814
Cost of revenue3,211,6823,222,184
Gross profit6,901,6066,609,630
Operating expenses:Research and development1,623,1601,790,024
Operating expenses:Selling, clinical and marketing4,816,7594,395,804
Operating expenses:General and administrative3,618,7393,944,056
Operating expenses:10,058,65810,129,884
Operating expenses:Loss from operations-3,157,052-3,520,254
Other expense (income), netInterest expense (income), net504,696-191,991
Other expense (income), netChange in fair value of derivative liabilities-839,064
Other expense (income), net)-334,368-191,991
Other expense (income), netLoss before income taxes-2,822,684-3,328,263
Other expense (income), netIncome tax expense186,715136,795
Other expense (income), netNet loss-3,009,399-3,465,058
Weighted average number of common shares outstanding:Basic and diluted42,269,13341,454,472
Net loss per share attributable to common stockholdersBasic and diluted-0.07-0.08

Income Statement

For the Three Months Ended March 31, — (unaudited)

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
GAAP net loss-3,009,399-3,465,058
Adjustments to reconcile to Adjusted EBITDA:Interest expense (income), net504,696-191,991
Adjustments to reconcile to Adjusted EBITDA:Depreciation expense291,590158,442
Adjustments to reconcile to Adjusted EBITDA:Stock-based compensation597,248540,204
Adjustments to reconcile to Adjusted EBITDA:Change in fair value of derivative liabilities-839,064
Adjustments to reconcile to Adjusted EBITDA:Income tax expense186,715136,795
Adjustments to reconcile to Adjusted EBITDA:Adjusted EBITDA-2,268,214-2,821,608

Balance Sheet

December 31, — CONDENSED CONSOLIDATED BALANCE SHEETS

March 31, – 2026 – (unaudited)December 31, – 2025
Current Assets:Cash and cash equivalents11,396,42614,132,027
Current Assets:Short-term investments4,299,9784,261,782
Current Assets:Accounts receivable, net4,824,5374,096,327
Current Assets:Inventories3,548,4243,123,089
Current Assets:Prepaid expenses and other current assets1,588,4531,943,860
Current Assets:Total Current Assets25,657,81827,557,085
Current Assets:Restricted cash575,000575,000
Current Assets:Operating lease assets with right of use6,499,2826,679,349
Current Assets:Equipment, net2,242,8112,212,901
Current Assets:Software development costs1,757,4021,590,864
Current Assets:Other assets21,37421,374
Current Assets:Total Assets36,753,68738,636,573
Current Liabilities:Accounts payable and accrued expenses7,020,8095,819,767
Current Liabilities:Current operating lease liability594,937494,662
Current Liabilities:Income taxes payable863,236813,260
Current Liabilities:Deferred revenue187,498218,222
Current Liabilities:Warrant derivative liability718,540999,418
Current Liabilities:Total Current Liabilities9,385,0208,345,329
Current Liabilities:Non-current operating lease liability7,440,7787,665,622
Current Liabilities:Long-term debt, net of discount10,926,20811,222,155
Current Liabilities:Total Liabilities27,752,00627,233,106
Stockholders’ Equity:Common stock3,8563,847
Stockholders’ Equity:Additional paid-in capital130,527,228129,929,989
Stockholders’ Equity:Accumulated other comprehensive loss174,882164,517
Stockholders’ Equity:Accumulated deficit-121,697,821-118,688,422
Stockholders’ Equity:Treasury stock, at cost-6,464-6,464
Stockholders’ Equity:Total Stockholders’ Equity9,001,68111,403,467
Stockholders’ Equity:Total Liabilities and Stockholders’ Equity36,753,68738,636,573

Cash Flow

For the Three Months Ended March 31, — CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

20262025
CASH FLOWS FROM OPERATING ACTIVITIESNet loss-3,009,399-3,465,058
Adjustments to reconcile net loss to net cash used in operations:Depreciation and amortization291,590158,442
Adjustments to reconcile net loss to net cash used in operations:Stock-based compensation597,248540,204
Adjustments to reconcile net loss to net cash used in operations:Accretion of discount on short-term investments-41,594-11,747
Adjustments to reconcile net loss to net cash used in operations:Bad debt expense51,643
Adjustments to reconcile net loss to net cash used in operations:Amortization of right-of-use assets180,067288,951
Adjustments to reconcile net loss to net cash used in operations:Amortization of deferred offering cost262,23929,039
Adjustments to reconcile net loss to net cash used in operations:Change in fair value of derivative liabilities-839,064
Adjustments to reconcile net loss to net cash used in operations:Other non-cash charges27,600-34,171
Changes in operating assets and liabilities:Accounts receivable-691,038-637,054
Changes in operating assets and liabilities:Inventories-447,321-550,772
Full release

Forward-Looking Statements

This press release contains forward-looking statements regarding the Company’s future business expectations, including expectations for second quarter and full year 2026 revenue, and operating leverage expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

These factors include, among other things:

• our ability to obtain sufficient reimbursement from third-party payers for our products;

• our dependence on external sources for the financing of our operations;

• our ability to scale the business to achieve positive cash flow from operations;

• our revenue concentration with patients who carry Medicare Part B;

• our ability to continue normal operations and patient interactions without supply chain disruption in order to deliver and fit our custom-fabricated devices;

• our marketing and commercialization efforts;

• our ability to obtain and maintain our strategic collaborations and to realize the intended results of such collaborations;

• our expectations as to our product development programs, including improving our existing products and developing new products;

• our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our products;

• our expectations as to our clinical research program and clinical results;

• our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others;

• our ability to gain and maintain regulatory approvals;

• our ability to compete and succeed in a highly competitive and evolving industry; and

• general market, economic, environmental and social factors that may affect the evaluation, fitting, delivery and sale of our products to patients.... (truncated) our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material or adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Contacts:

Myomo: ir@myomo.com

Alliance Advisors IR:

Bruce Voss bvoss@allianceadvisors.com

310-691-7100

(Tables follow)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Myomo earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.